{
 "id": "schizophrenia",
 "name": "Schizophrenia",
 "aliases": [],
 "acronyms": [],
 "bodySystem": "mental-health",
 "parent": null,
 "children": [],
 "edition": "2026-11",
 "merkleRoot": "006ab9a329709cbe7f56a0e1a7c4a02f897655cdfecf9ca34d199690095adcb6",
 "builtFrom": "program.status and program.eligibility facts, grouped by the condition registry",
 "counts": {
  "open": 1,
  "limited": 0,
  "waitlist": 0,
  "closed": 1
 },
 "funds": [
  {
   "fund": "Schizophrenia - Medicare Access",
   "organization": "HealthWell Foundation",
   "status": "open",
   "dateOnPage": null,
   "awardLevelUsd": null,
   "insuranceTypes": null,
   "pageSays": "The page lists the fund as Open.",
   "readOn": "2026-11-08",
   "source": "https://www.healthwellfoundation.org/disease-funds/"
  },
  {
   "fund": "Schizophrenia",
   "organization": "TotalAssist (Patient Advocate Foundation copay funds)",
   "status": "closed",
   "dateOnPage": null,
   "awardLevelUsd": 4200,
   "insuranceTypes": [
    "Medicaid",
    "Medicare",
    "TRICARE"
   ],
   "pageSays": "The page lists the fund as Closed.",
   "readOn": "2026-11-08",
   "source": "https://totalassist.org/funds/"
  }
 ],
 "drugsWhoseLabelNamesThisCondition": [
  {
   "ingredient": "BREXPIPRAZOLE",
   "pages": [
    {
     "brand": "Rexulti",
     "url": "https://omnirx.org/negotiated-drugs/rexulti"
    }
   ],
   "labelSentence": "Adjunctive treatment to antidepressants for major depressive disorder (MDD) in adults Treatment of schizophrenia in adults and pediatric patients ages 13 years and older Treatment of agitation associated with dementia due to Alzheimer's ...",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%222d301358-6291-4ec1-bd87-37b4ad9bd850%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Mental Health Medication Assistance (Multiple Programs)",
     "url": "https://omnirx.org/assistance/mental-health-medication-assistance",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": {
    "usd30DaySupply": null,
    "effective": "2028-01-01",
    "source": "https://www.cms.gov/initiatives/medicare-prescription-drug-affordability/overview/medicare-drug-price-negotiation-program/selected-drugs-negotiated-prices"
   }
  },
  {
   "ingredient": "CARIPRAZINE",
   "pages": [
    {
     "brand": "Vraylar",
     "url": "https://omnirx.org/negotiated-drugs/vraylar"
    }
   ],
   "labelSentence": "Treatment of schizophrenia in adult and pediatric patients 13 years of age and older [see Clinical Studies ( 14.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%224b5f7c65-aa2d-452a-b3db-bc85c06ff12f%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Mental Health Medication Assistance (Multiple Programs)",
     "url": "https://omnirx.org/assistance/mental-health-medication-assistance",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": null,
     "statusRead": null
    },
    {
     "name": "myAbbVie Assist",
     "url": "https://omnirx.org/assistance/abbvie-myabbvie-assist",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": "Available medicines (myAbbVie Assist)",
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": {
    "usd30DaySupply": 770,
    "effective": "2027-01-01",
    "source": "https://www.cms.gov/initiatives/medicare-prescription-drug-affordability/overview/medicare-drug-price-negotiation-program/selected-drugs-negotiated-prices"
   }
  },
  {
   "ingredient": "Aripiprazole Lauroxil",
   "pages": [
    {
     "brand": "Aristada",
     "url": "https://omnirx.org/medicines/aristada"
    }
   ],
   "labelSentence": "ARISTADA is indicated for the treatment of schizophrenia in adults [see Clinical Studies ( 14 )].",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%2217a8d11b-73b0-4833-a0b4-cf1ef85edefb%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "ARISTADA Patient Assistance Program",
     "url": "https://www.aristadahcp.com/access-support",
     "programPageIsExternal": true,
     "inCurrentList": true,
     "note": null,
     "listKind": "Single-product program page (ARISTADA)",
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Lumateperone Tosylate",
   "pages": [
    {
     "brand": "Caplyta",
     "url": "https://omnirx.org/medicines/caplyta"
    }
   ],
   "labelSentence": "Treatment of schizophrenia in adults [see Clinical Studies (14.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%22db730b06-6351-47fd-8183-e61e61bbead5%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Johnson & Johnson Patient Assistance Program",
     "url": "https://omnirx.org/assistance/johnson-and-johnson-pap",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": "Medicines in the Quick Reference Guide picker on the program page",
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Paliperidone Palmitate",
   "pages": [
    {
     "brand": "Invega Sustenna",
     "url": "https://omnirx.org/medicines/invega-sustenna"
    },
    {
     "brand": "Invega Trinza",
     "url": "https://omnirx.org/medicines/invega-trinza"
    },
    {
     "brand": "Invega Hafyera",
     "url": "https://omnirx.org/medicines/invega-hafyera"
    }
   ],
   "labelSentence": "Schizophrenia in adults [see Clinical Studies (14.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%221af14e42-951d-414d-8564-5d5fce138554%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "J&J Patient Assistance Foundation (JJPAF)",
     "url": "https://omnirx.org/assistance/johnson-and-johnson-pap",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": "Medicines in the Quick Reference Guide picker on the program page",
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Risperidone Microspheres",
   "pages": [
    {
     "brand": "Risperdal Consta",
     "url": "https://omnirx.org/medicines/risperdal-consta"
    }
   ],
   "labelSentence": "Treatment of schizophrenia ( 1.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%2200c569bf-3bfa-4869-bc0d-e4b36887b7c1%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Johnson & Johnson Patient Assistance Program",
     "url": "https://omnirx.org/assistance/johnson-and-johnson-pap",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": "Medicines in the Quick Reference Guide picker on the program page",
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Aripiprazole",
   "pages": [
    {
     "brand": "Abilify Maintena",
     "url": "https://omnirx.org/medicines/abilify-maintena"
    }
   ],
   "labelSentence": "Schizophrenia • Irritability Associated with Autistic Disorder • Treatment of Tourette’s Disorder Aripiprazole is an atypical antipsychotic.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%2202a4af27-c83c-4166-950c-7a1cb12d198d%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Lurasidone HCl",
   "pages": [],
   "labelSentence": "Treatment of adult and adolescent patients (13 to 17 years) with schizophrenia [see Clinical Studies (14.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%22296811cf-cba8-16c2-e063-6294a90acfa6%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [],
   "medicareNegotiatedPrice": null
  }
 ],
 "fundsForRelatedCosts": [],
 "note": "Each status is what the fund page said on readOn. It is not an eligibility determination. We hold only the organizations we read; no fund here does not mean no fund exists.",
 "licence": "CC BY 4.0 for the OmniRx compilation"
}